Current clinical status of pulsatile pediatric circulatory support.
Whereas circulatory support with pulsatile assist devices is an established therapy in adults today, it remains unusual and extremely challenging in children. Specifically designed smaller size pumps are, to date, only available in Europe. This review summarizes the experience with both adult size pumps in the U.S. and pediatric pumps in Europe. Thoratec ventricular assist devices (VADs) were implanted in 101 patients worldwide who were between 7 and 17 years of age. Survival in this group was 68.8%, which is comparable with that in adult patients and was independent of age or body size. Berlin Heart VADs, available in several sizes, were implanted at the Deutsches Herzzentrum Berlin in 45 patients between 2 days and 16 years old. Survival in patients with myocarditis and cardiomyopathy was 66.7% and 71.4%, respectively; overall survival was 48.9%. In a number of European centers, 64 children up to 16 years of age received Medos devices, which are also available in several sizes, with an overall survival of 36.2%, similar for all pump sizes. End-stage congenital heart defects or failure to wean off bypass carried a poorer prognosis than cardiomyopathies or myocarditis for all devices.
Reinhartz
Olaf
O
Department of Cardiothoracic Surgery, University of California at San Francisco, 94143, USA.
Stiller
Brigitte
B
Eilers
Rolf
R
Farrar
David J
DJ
D001824:Body Constitution; D009202:Cardiomyopathies / Q000628:therapy*; D002648:Child; D006353:Heart-Assist Devices; D006801:Humans; D009205:Myocarditis / Q000628:therapy*; D011673:Pulsatile Flow